uploads///Chart  USST

How Allergan’s US Specialized Therapeutics Segment Performed

By

Jul. 17 2017, Updated 6:37 a.m. ET

The US Specialized Therapeutics segment

Allergan’s (AGN) US Specialized Therapeutics segment includes branded products from therapeutic areas such as eyecare, medical aesthetics, medical dermatology, neuroscience, and urology.

The US Specialized Therapeutics reported revenues of $1.48 billion in 1Q17, which represented a 14.1% growth as over its $1.30 billion in 1Q16.

Article continues below advertisement

Franchise performance

The performances of Allergan’s US Specialized Therapeutics franchises in 1Q17 were as follows:

  • The US medical aesthetics franchise includes facial aesthetics and medical dermatology products as well as a wide range of fillers, silicone gel, and saline breast implants under Botox and Kybella. This franchise saw revenues of $318.7 million in 1Q17, compared with $279.4 million in 1Q16.
  • The eyecare franchise includes growth drivers like Restasis, Alphagan, Ozurdex, and other eye care products. This franchise saw revenues of $553.1 million in 1Q17, or 3.8% higher than in 1Q16.
  • The regenerative franchise includes Alloderm and other products. This franchise reported revenues of $75.5 million for 1Q17.

Other performances

The plastic surgery franchise includes breast implants and breast reconstruction products, as well as other plastic surgery products. This franchise reported revenues of $54.3 million for 1Q17, or 12.9% higher than the $48.1 million in 1Q16. Below are a few other performance rundowns for this segment:

  • The medical dermatology franchise includes advanced dermatology products like Aczone, Botox Hyperhidrosis, Tazorac, and other products. This franchise reported revenues of $86.6 million for 1Q17, compared with $69.0 million in 1Q16.
  • Skincare products include the Latisse brand of products, and this franchise reported revenues of $41.6 million in 1Q17—a decline from 1Q16.
  • The segment’s neuroscience and urology franchise includes products from Botox therapeutics and other products like Rapaflo. The franchise reported revenues of $334.7 million in 1Q17, or 9.1% higher than the $306.8 million in 1Q16.

To divest risk, investors can consider ETFs like the iShares US Healthcare ETF (IYH), which has 3.3% of its total assets in Allergan. IYH also has 6.8% in Pfizer (PFE), 3.4% in AbbVie (ABBV), and 3.0% in Gilead Sciences (GILD).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.